Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mydriatic Microdrops vs Standard Dose for ROP Examination
NCT06288321Phase 1Completed
- Sponsor
- The University of Hong Kong
- Start
- Aug 2022
- Primary completion
- Mar 2023
- Modality
- Small Molecules, Device-based Delivery
- Countries
- 1
01
Overview
Phase 1, randomised trial of Mydriasert in retinopathy of prematurity (ROP) (2 arms), sponsored by The University of Hong Kong. Primary endpoint: Successfulness of a Retinopathy of Prematurity (ROP) exam. Started Aug 2022; status: completed.
02
Drugs
Mydriasert
03
Conditions
retinopathy of prematurity (ROP)
Beyond the preview
Go deeper on NCT06288321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06288321.